| Literature DB >> 35893648 |
Nurkhalida Kamal1, Nurul Syahidah Mio Asni1, Ivana Nur Allisya Rozlan1, Muhammad Aniq Hamzah Mohd Azmi2, Noor Wini Mazlan2,3, Ahmed Mediani1, Syarul Nataqain Baharum1, Jalifah Latip4, Suvik Assaw3,5, Ru Angelie Edrada-Ebel6.
Abstract
The genus Vitex is also known as a chaste tree, in which it is a large shrub native to the tropical and subtropical regions of the world. A diverse range of species is distributed throughout Southern Europe, the Mediterranean, and Central Asia. The Vitex tree, including its leaves and fruits, has been used for herbal remedies in the form of pastes, decoctions, and dried fruits since ancient times. This article aimed to prepare a comprehensive review of traditional uses and secondary metabolites derived from Vitex sp., including the chemical compounds, biological activities, application of Vitex in human clinical trials, toxicology and safety, marketed products, and patents. The scientific findings were obtained using a number of search engines and databases, including Google Scholar, PMC, and ScienceDirect. Vitex species are well known in pharmacology to have medicinal values, such as anti-inflammatory, antibacterial, antifungal, antimicrobial, antioxidant, and anticancer properties. Previous studies reported that some species are proven to be effective in treating diseases, such as diabetes, and improving female health. A total of 161 compounds from different Vitex species are reported, covering the literature from 1982 to 2022. A chemical analysis report of various studies identified that Vitex exhibited a wide range of phytoconstituents, such as iridoid, diterpenoid, ecdysteroid, and flavonoid and phenolic compounds. Apart from that, the review will also discuss the application of Vitex in human clinical trials, toxicology and safety, marketed products, and patents of the genus. While the extracts of the genus have been made into many commercial products, including supplements and essential oils, most of them are made to be used by women to improve menstrual conditions and relieve premenstrual syndrome. Among the species, Vitex agnus-castus L. is the only one that has been reported to undergo clinical trials, mainly related to the use of the genus for the treatment of mastalgia, menstrual bleeding problems, amenorrhea, menorrhagia, luteal insufficiency, and premenstrual syndrome. Overall, the review addresses recent therapeutic breakthroughs and identifies research gaps that should be explored for prospective research work.Entities:
Keywords: Vitex; biological activity; health application; phytochemistry; tradional medicinal use
Year: 2022 PMID: 35893648 PMCID: PMC9370779 DOI: 10.3390/plants11151944
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Bioactive secondary metabolites and biological activities of Vitex sp.
Figure 2Prisma flow diagram of the study.
Summary of traditional applications of various Vitex species in medicine.
| Traditional Uses | Plant Parts Used | References | |
|---|---|---|---|
| Increase lactation | Shoot, fruit | [ | |
| Post-partum bath | Leaf | [ | |
| Diarrhea, dysentery, flatulence, indigestion, and cholera | Root, bark, flower | [ | |
| Headache | Leaf | [ | |
| Cough, sore throat | Leaf | [ | |
| Rheumatism | Root, leaf | [ | |
| Hives, cellulitis, carbuncle | Leaf | [ | |
| Catarrhal fever, muffled hearing | Leaf | [ | |
| Decrease sexual drive | Leaf, seed, fruit | [ | |
| Menstrual irregularities, infertility, premenstrual syndrome, acne, digestive complaint, sedative | - | [ | |
| Increase lactation | Leaf, fruit | [ | |
| Inflammation, injury, snake and spider antivenom, epilepsy, madness, insanity | - | [ | |
| Flatulence, urination, dropsy, splenic disease | Seed | [ | |
| Pain due to chills | Leaf | [ | |
| Calming agent for hysteria | Fruit | [ | |
| Joint pain, ringworm, leprosy, skin rashes | Leaf | [ | |
| Intermittent fever, catarrh, headache | Leaf | [ | |
| Pitta in blood | Leaf | [ | |
| Tonic, expectorant, febrifuge | Root | [ | |
| Headache, migraine, common fever, eye pain, cancer | Fruit | [ | |
| Decrease sexual drive | - | [ | |
| Dysentery | Stem, leaf | [ | |
| Rheumatism, sprained joint | Leaf | [ | |
| Headache | Leaf | [ | |
| Oral infection, inflammation | - | [ | |
| Diabetes | Leaf, bark | [ | |
| Jaundice, numbness of face and eyes, urethritis | Bark | [ | |
| Blackwater fever, malaria | Bark, root, leaf | [ | |
| Chest pain, joint pain | Bark | [ |
Figure 3Chemical structures of iridoids 1–24 found in Vitex species.
Figure 4Chemical structures of diterpenoids 25–102 found in Vitex species.
Figure 5Chemical structures of ecdysteroids 103–114 found in Vitex species.
Figure 6Chemical structures of flavonoids 115–127 found in Vitex species.
Figure 7Chemical structures of compounds 128–161 found in Vitex species.
Summary of different compounds isolated from various Vitex species and their biological activities.
| Compound Names | Structural Type | Biological Activities | References | |
|---|---|---|---|---|
| Negundoside ( | Iridoids | Showed protective effects against CCl4-induced toxicity in HuH-7 cells and oxidative stress. | [ | |
| Nishindaside ( | Iridoids | - | [ | |
| Lagundinin ( | Iridoids | - | [ | |
| Carboxylic acid derivative ( | Iridoids | - | [ | |
| Tarumal ( | Iridoids | Inhibited COX-2 with IC50 value of 0.15 ± 0.21 mg/mL. However, it only showed low inhibition of COX-1 and no cytotoxicity against African green monkey kidney (Vero) cell lines. | [ | |
| Pedunculariside ( | Iridoids | - | [ | |
| Agnucastoside A-C ( | Iridoids | All three compounds showed no antimicrobial and anticancer activities. | [ | |
| 6′- | Iridoids | Compounds | [ | |
| Pinnatoside ( | Iridoid | - | [ | |
| Agnusoside ( | Iridoid | Exhibited moderate anti-inflammatory activity using NO production induced by lipopolysaccharide. | [ | |
| Vitexnegheteroins K and L ( | Iridoid glycoside | Iridoid glycosides | [ | |
| 10- | Iridoid glycoside | No inhibitory activity on NO production. | [ | |
| (1 | Iridoid glycoside | IC50 value of 90.05 M and moderate inhibitory activities on NO production with LPS-induced RAW 264.7 macrophages. | [ | |
| Nishindacin A ( | Iridoids | Compounds | [ | |
| Labdane-type diterpenes | Diterpenoids | No antioxidant activity. |
| [ |
| Labdane-type diterpene congeners | Diterpenoids | No bioactivity was demonstrated. Compounds |
| [ |
| Viteagnusin C-H and J ( | Diterpenoids | - | [ | |
| Labdane diterpene 6 | Diterpenoid | It showed strong affinity to the dopamine-D2-receptor with IC50 value of 15 μg/mL. | [ | |
| Vitexlactam A ( | Diterpenoid | - | [ | |
| Vitexlactam B and C ( | Diterpenoids | Compound | [ | |
| Vitetrifolin H and I ( | Diterpenoids | Both compounds inhibited HeLa cell proliferation with IC50 between 4–28 μM. Compound | [ | |
| Viteagnusin I ( | Diterpenoid | No activity was shown on opioid receptor assays DOR and MOR. | [ | |
| Two diastereomers of negundol ( | Diterpenoids | Exhibited antifungal activity with MIC values in the range of 16–64 μg/mL. | [ | |
| 6 | Diterpenoids | Active against | [ | |
| Vitrifolin A ( | Diterpenoid | Exhibited moderate inhibitory effect against NO production in lipopolysaccaride-activated mouse macrophages. | [ | |
| Vitextrifolin A-G ( | Diterpenoids | They were inactive against A549, HCT116, HL60, and ZR-75–30 cell lines. | [ | |
| Vitrifolin B ( | Diterpenoid | - |
| [ |
| 12-epivitexolide A ( | Diterpenoid | Exhibited moderate antibacterial and cytotoxic activity on the HCT-116 and MRC15 cell lines. | [ | |
| Vitexolides B and C ( | Diterpenoid | Exhibited cytotoxic activity on the HCT-116 cell lines. | [ | |
| Vitexolides E ( | Diterpenoid | Exhibited moderate antibacterial and cytotoxic activity on the HCT-116 and MRC15 cell lines. | [ | |
| Vitexolin A ( | Diterpenoid | Exhibited cytotoxic activity on the HCT-116 cell lines. | [ | |
| Vitexolin B ( | Diterpenoid | Exhibited moderate antibacterial and cytotoxic activity on the HCT-116 and MRC15 cell lines. | [ | |
| Chastol ( | Diterpenoid | - | [ | |
| Epichastol ( | Diterpenoid | - | [ | |
| Vitepyrroloids A−D ( | Diterpenoids | Exhibited cytotoxic activity against CNE1 cells with IC50 value of 8.7 μM. | [ | |
| Labdane-types ( | Diterpenoids | - | [ | |
| Halimane ( | Diterpenoids | Compounds | [ | |
| Clerodane ( | Diterpenoids | Compounds | [ | |
| Viterotulin C ( | Diterpenoids | Both compounds significantly inhibited NF-κB activation ( |
| [ |
| (3 | Diterpenoid | No inhibitory activity on NO production in LPS-induced RAW 264.7 macrophages up to concentration of 100 μM. | [ | |
| (3 | Diterpenoids | Possessed inhibitory activities on LPS-induced NO production. Compounds | [ | |
| 9-epivitexnegundin ( | Diterpenoid | Evaluated for its antimicrobial activity but the activity was not mentioned. | [ | |
| Abieta-11(12)-ene-9 | Diterpenoid | All compounds exhibited antimalarial activity compounds |
| [ |
| Pinnatasterone ( | Ecdysteroid | Exhibited weak activity against | [ | |
| Canescensterone ( | Ecdysteroid | - | [ | |
| 26-hydroxypinnatasterone ( | Ecdysteroid | - | [ | |
| 24-epi-pinnatasterone ( | Ecdysteroids | Exhibited very weak moulting activity in | [ | |
| 21-hydroxyshidasterone ( | Ecdysteroids | Exhibited anti-inflammatory activity in rat paw oedema development assay at 100 mg/kg dose. | [ | |
| 20,24-dihydroxy-24-hydroxymethylecdysone ( | Ecdysteroid | This compund could be used in chemical defence against non-adapted herbivores. It also could be used as new and additional characteristic compound parameter in compound identification to reduce dereplication and false positives. |
| [ |
| Luteolin 6-C-(4″-methyl-6″- | Flavonoids | - | [ | |
| Vitegnoside ( | Flavonoids | Exhibited antifungal activity against | [ | |
| Vitecetin ( | Flavonoids | Exhibited better antileishmanial activity than sodium antimonygluconate (SAG) with IC50 values of 2.4 and 58.5 mM for promastigote, and 0.93 and 36.2 mM for amastigotes. The compound was less toxic than SAG towards THP-1 with CC50 values of 123.7 mM and 364.3 mM, respectively. | [ | |
| 2-(5-methoxyphenyl)-3,4′,5,7,8-trihydroxychroman-4-one ( | Flavonoid | All compounds exhibited moderate trypanocidal activity against |
| [ |
| 4′-acetoxy-5-hydroxy-6,7-dimethoxyflavone ( | Flavonoid | - |
| [ |
| 4,5-diethyl-3′-ethoxy-pyro flavone ( | Flavonoid | Exhibited significant antifilarial activity in dose dependent manner. | [ | |
| Vitexdoin F ( | Lignan | Exhibited stronger activity than ascorbic acid using DPPH radical-scavenging assays. | [ | |
| Vitexnegheteroin E ( | Lignan | Exhibited antioxidant and inhibitory activities on lipopolysaccharide-induced NO. | [ | |
| Vitexnegheteroin F ( | Lignan | Exhibited moderate cytotoxic activities against human liver carcinoma (HepG2) cell lines. | [ | |
| Vitexnegheteroin G ( | Lignan | Exhibited antioxidant activities using ABTS scavenging activities. | [ | |
| 9-hydroxysesamin ( | Lignan | - | [ | |
| (3 | Lignan | - | [ | |
| 6,7,4′-trihydroxy-3′-methoxy-2,3-cycloligna-1,4-dien-2a,3a-olide ( | Lignan | - | [ | |
| 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-acetoxymethyl-7-methoxy-3,4-dihydro-2-naphthaldehyde ( | Lignan | - | [ | |
| 3 | Lignan | - | [ | |
| Vitekwangin A ( | Lignan | Both compounds showed minor cytotoxicity on RAW 264.7 cells with IC50 greater than 80 µM. At lower concentrations, compounds | [ | |
| (9 | Monoterpenoids | All compounds showed anti-inflammatory activity and obvious inhibitory activity (IC50 > 100 μM), respectively. | [ | |
| Cannabifolins | Triterpenoids | Compound | [ | |
| 3 | Triterpenoid | Exhibited cytotoxic activity against HL-60, SGC-7901, PANC-01, and Eca-109 cell lines. | [ | |
| Vitexnegheteroin H ( | Triterpenoid | No inhibition on NO production. | [ | |
| 1 | Triterpenoid | - | [ | |
| 2 | Triterpenoid | - | [ | |
| Vitexnegheteroin A-D ( | Phenolic glycosides | All compounds exhibited antioxidant and NO inhibitory activities. | [ | |
| Methyl(6- | Phenolic glycoside | Exhibited antioxidant and NO inhibitory activities. | [ | |
| Breynioside A ( | Phenolic glycosides | Exhibited antioxidant and NO inhibitory activities. | [ | |
| Vitexnegheteroin M ( | Phenolic glycoside | Exhibited weak inhibitory effects on NO production with LPS-stimulate (IC50 > 100 µM) and no effect of cytotoxicity on BV-2 cells. | [ | |
| Methyl 3-(2-(5-hydroxy-6-methoxy-4-oxo-4 | Chromone derivatives | The derivatives from | [ |
Information on Vitex products available in the market.
| Product Name, Unit Size, and Source | Country | Indication(s) for Use, Dosage Information, and Calculated Maximum Daily Intake |
|---|---|---|
| Nature’s Answer | United States | This product may help to support woman’s hormonal balance. Suggested to be use as a supplement for diet. Take one capsule once a day with food or water. |
| Thompson’s-One-A-Day Vitex | New Zealand | This product may help relieve PMS and regulate menstrual cycle. For adults, take 1 capsule daily, first thing in the morning or as prescribed by a healthcare professional. Store below 30 °C in a dry place. |
| Solaray Vitex (Chastetree) | United States | |
| Blackmores | Australia | This product may help to regulate menstrual cycle, relieves breast pain and swelling. It is used traditionally in Western herbal medicine to help regulate the menstruation cycle. Only can be taken by adults. Take 1 tablet 3 times a day, or as prescribed by professionals. |
| Kordel’s Vitex | Malaysia | Kordel’s vitex is traditional used to relieves premenstrual discomforts and to regulate menstruation. Only can be consume by adults. Take 1–2 capsules daily first thing in the morning, preferably before breakfast, or as directed by your health care professional. |
List of patents for Vitex species.
| No. | Patent No./ Country | Title | Details | References |
|---|---|---|---|---|
| 1 | ES2190383A1 | The present invention provides a | [ | |
| 2 | US8637099B2 | Use of | The present invention relates to the use of fruit extract from | [ |
| 3 | USPP25914P3 | A new and distinct cultivar of | [ | |
| 4 | 20160135348 | The present innovation relates to a distinct and new cultivar of | [ |